Plastic Surgery Doctors in Athens, GA Accepting Medicare

6 Plastic Surgery doctors found. Showing 1 - 6

Dr. Stephen Lober, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2325 Prince Ave, Athens, GA 30606 Phone: 706-546-0280    Fax: 706-548-0258

James Lewis Moore, MD Plastic Surgery Medicare: Medicare Enrolled Practice Location: 740 Prince Ave, Bldg 10, Athens, GA 30606 Phone: 706-850-3603    Fax: 706-850-8856

Dr. John Hurteau, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2325 Prince Ave, Athens, GA 30606 Phone: 706-546-0280    Fax: 706-548-0258

Cesar Augustus Gumucio, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 489 N Milledge Ave, Athens, GA 30601 Phone: 706-613-6650    Fax: 706-613-6868

Chelsea Meredith Venditto, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 489 N Milledge Ave, Athens, GA 30601 Phone: 706-363-0256    Fax: 706-622-4360

Mr. Clyde Edwin Pittman, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3320 Old Jefferson Road, Bldg 100, Athens, GA 30607 Phone: 706-353-3600    Fax: 706-353-3777

News Archive

Tolvaptan shows promise in treating autosomal dominant polycystic kidney disease

A drug therapy shows promise for treating an inherited form of kidney disease called autosomal dominant polycystic kidney disease (ADPKD), Mayo Clinic researchers say.

New lidocaine-prilocaine spray may treat premature ejaculation

A new topical spray, is a safe and effective treatment for premature ejaculation.

Imaging tumor stiffness could aid delivery of treatment to most challenging cancers

Using a non-invasive imaging technique that measures the stiffness of tissues gives crucial new information about cancer architecture and could aid the delivery of treatment to the most challenging tumors, new research shows.

InNexus Biotechnology, NCI amend Collaborative Agreement

InNexus Biotechnology Inc., a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced the Company and the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), have amended the Collaborative Agreement announced on May 27, 2010, involving research on technologies developed by InNexus.

Read more Medical News

› Verified 9 days ago